Chemotherapy re-use versus anti-angiogenic monotherapy as the third-line treatment of patients with metastatic colorectal cancer: a real-world cohort study

Chemotherapy re-use versus anti-angiogenic monotherapy as the third-line treatment of patients with metastatic colorectal cancer: a real-world cohort study

Abstract Background There are various recommendations for third-line treatment in mCRC, however, there is no consensus on who is more suitable for particular strategy. Chemotherapy re-use in third-line setting is a common option in clinical practice. This study aimed to investigate the efficacy of t...

Full description

Bibliographic Details
Main Authors: Jingjing Duan, Lila Zhu, Yinghui Shi, Weixue Wang, Tongtong Wang, Tao Ning, Le Zhang, Ming Bai, Hongli Li, Rui Liu, Shaohua Ge, Xia Wang, Yuchong Yang, Zhi Ji, Feixue Wang, Yansha Sun, Yi Ba, Ting Deng
Format: Article
Language:English
Published: BMC 2024-03-01
Series:BMC Cancer
Subjects:
Colorectal cancer
Third-line therapy
Chemotherapy
Real-world evidence
Online Access:https://doi.org/10.1186/s12885-024-12072-5

Internet

https://doi.org/10.1186/s12885-024-12072-5

Similar Items